Who Paid My Doc
Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL
Research payments
$10,597,284
Through program year 2025, $10,597,284 in research payments was reported against Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL, across 1,661 payments.
- Paid by (largest first)
- Genentech, Inc.; F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $9,034 | 2 |
| 2024 | Research | $678,225 | 313 |
| 2023 | Research | $3,633,927 | 632 |
| 2022 | Research | $4,302,996 | 472 |
| 2021 | Research | $1,973,102 | 242 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ari Vanderwalde Germantown, TN Named on 105 payments
- Manuel Modiano Revah Tucson, AZ Named on 54 payments
- Edward Arrowsmith Chattanooga, TN Named on 52 payments
- Maen Hussein Warwick, RI Named on 45 payments
- Lasika Seneviratne Los Angeles, CA Named on 41 payments
- Jeffrey Bubis Philadelphia, PA Named on 39 payments
- Dennis Slater Norwich, CT Named on 38 payments
- Ray Page Fort Worth, TX Named on 38 payments
- Richard Zuniga Lowell, MA Named on 34 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.